Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab Safety Study After Sequential Chemoradiation in Stage III NSCLC
NCT03693300Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2019
- Primary completion
- Dec 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 6
01
Overview
Phase 2, open-label trial of durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Number of Patients With Grade 3 and Grade 4 Treatment-related Adverse Events up to 6 months. Started Apr 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03693300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693300.